Key result
Familial combined hyperlipidemia and familial hypertriglyceridemia were both associated with an identical increased risk of coronary artery disease (OR 2.0; P=0.003 and P=0.002, respectively).
Why the study?
Does familial combined hyperlipidemia or familial hypertriglyceridemia increase the risk of premature coronary artery disease compared to controls?
Case-Control (n=627)
Does familial combined hyperlipidemia or familial hypertriglyceridemia increase the risk of premature coronary artery disease compared to controls?
Effect estimate: OR 2.0
p-value: p=0.003 and 0.002
FCHL and FHTG carry a similar increased risk for premature CAD, which is largely driven by the high prevalence of concurrent metabolic syndrome, challenging the conventional wisdom that FHTG is benign.
No takes yet. Share an insight, caveat, or question.
Supports equivalent CAD risk with FHTG and FCHL; challenges benign perception of FHTG but leaves open need for prospective confirmation.
Hopkins et al. (2003) conducted a case-control in Familial Combined Hyperlipidemia and Familial Hypertriglyceridemia (n=627). Familial combined hyperlipidemia (FCHL) and familial hypertriglyceridemia (FHTG) vs. Controls without FCHL or FHTG was evaluated on Coronary artery disease (CAD) (OR 2.0, p=0.003 and 0.002). Familial combined hyperlipidemia and familial hypertriglyceridemia were both associated with an identical increased risk of coronary artery disease (OR 2.0; P=0.003 and P=0.002, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: